Altimmune's GLP-1/glucagon shot reduces drinking in Phase 2 alcohol use disorder trial
read at Endpoints ↗Positive readoutPositive
Altimmune announced results from its mid‑stage Phase 2 RECLAIM trial evaluating pemvidutide, a GLP‑1/glucagon dual agonist, in patients with moderate‑to‑severe alcohol use disorder.
The trial compared weekly injections of pemvidutide against placebo and found that participants receiving the drug reduced their alcohol consumption relative to the control group.
The company highlighted the reduction as a promising signal for a new therapeutic approach to alcoholism, though the data remain preliminary pending further study.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism”
read at Endpoints ↗85 words · retrieved Jul 28
comments(0)
5-min edit window · permanent after that